The first new asthma pill in decades, could help adults with severe asthma.
An experimental pill created by University of Leicester researchers, produced promising results in a small clinical trial, for a treatment for patients with asthma.
Asthma, a disease of the lungs that causes breathlessness, chest tightness, and coughing, for the estimated 39.5 million people in the United States.
Asthma pill could reduce symptoms in severe sufferers
The new pill improved function on lungs and on inflammation of the airway.
Commenting on the results, Professor Christopher Brightling, who led the project, said:
“A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
Most treatments might improve some of these features of disease, but with Fevipiprant, improvements were seen with all of the types of tests. We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms – making it a ‘game changer’ for future treatment.”
source University of Leicester